
Brief intro:
- Author: Lifang Ma, Hui Huang, Wei Feng, Liang Chen, Lili Xia, Yongchun Yu, Jiayi Wang, Yu Chen
- Journal: Advanced Functional Materials
- Doi: https://www.doi.org/10.1002/adfm.202208220
- Publication Date: 2022 Oct 11
Products/Services used in the paper
Quotation shows PackGene:CRISPR-Cas9-Mediated HEPH Gene Knock-Out: HEPH-deleted (HEPH−/−) cells were generated using the CRISPR-Cas9-mediated gene knockout technology. Lentivirus-based vectors expressed sg-control and gene-specific sgRNAs targeted HEPH (#1: CTCTGAATGTTCTCTTCCC and #2: TGC TGTTCATTGCAGTCCTTG) were purchased from PackGene (Guangzhou, China).
Research Field:cancer treatment
Abstract
The emerging chemodynamic therapy employs an iron-based catalytic Fenton reaction to transform less-reactive endogenous hydrogen peroxide within the tumor microenvironment (TME) into a highly toxic hydroxyl radical for killing cancer cells. However, the effective deployment of chemodynamic modality remains challenging, mired by a paucity of Fenton agents and overexpressed antioxidant glutathione (GSH) in cancer cells. Herein, a clay-based 2D vermiculite nanosheet as a self-reinforcing chemodynamic nanoagent for efficient lung cancer treatment is engineered. The engineered 2D vermiculite nanosheets are not only biocompatible with normal cells but also capable of regulating the TME through depleting GSH, which ameliorates the antioxidant activity of cancer cells. Meanwhile, GSH consumption results in increased intracellular reactive oxygen species content and enhanced lipid peroxidation level, thus inducing ferroptosis and augmenting chemodynamic cell-killing efficacy. In particular, the ferrous oxidase hephaestin is the direct therapeutic target for 2D vermiculite nanosheets to fight against lung cancer cells. Systematic in vivo evaluations on a xenografted tumor model verify the favorable biosafety and effective tumor suppression capacity of the engineered 2D vermiculite nanosheets-mediated chemodynamic tumor therapy by inducing desirable ferroptosis. Therefore, the developed vermiculite nanosheets represent the paradigm of 2D ferroptosis-inducing nanomedicine for synergistic and efficient cancer treatment.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
